EKF Diagnostics Holdings plc (OTCMKTS: EKDHF) is a global in vitro diagnostics company that develops, manufactures and markets a broad range of point-of-care and laboratory analyzers, reagents and consumables. The company’s product portfolio addresses key segments of the diagnostic testing market, including haematology, biochemistry, immunoassay, haemostasis and diabetes monitoring.
EKF Diagnostics offers peripheral blood analyzers designed for use in clinical laboratories, hospitals and veterinary clinics, along with handheld and benchtop devices for rapid on-site testing. Its reagent kits and test strips support measurement of haemoglobin, haemoglobin A1c, liver and kidney function enzymes, cardiac markers and other critical analytes. The company also supplies sample preparation equipment and quality control materials to ensure accuracy and reliability in diagnostic workflows.
Headquartered in Barleben, Germany, EKF Diagnostics operates additional manufacturing and research facilities in the UK and sales offices in North America, Europe, Latin America and Asia. Its products are distributed through a network of direct sales teams and third-party distributors, serving healthcare providers, veterinary practices, academic researchers and industrial laboratories worldwide.
Founded in the mid-1990s and publicly listed on the London Stock Exchange’s AIM market, EKF Diagnostics has expanded its global footprint through a combination of organic growth and strategic acquisitions. The company is led by an executive team with deep expertise in the life sciences and diagnostics industries, focused on innovation, quality and customer support.
AI Generated. May Contain Errors.
